감염증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 감염증별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,407,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,820,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,646,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

감염증 치료제 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 감염증 치료제 시장 규모는 2030년까지 2,839억 1,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 3.5%의 CAGR을 기록할 것으로 예상됩니다.

이 시장은 주로 인간면역결핍바이러스(HIV), 인유두종바이러스(HPV), 결핵, 간염의 전 세계적인 증가가 주요 요인으로 작용하고 있습니다.

정부 기관과 민간 기업들은 감염성 질환의 예방, 진단, 치료를 위해 헬스케어 분야에 많은 투자를 하고 있으며, 감염성 질환을 치료하기 위한 신약 개발에 대한 투자 증가와 이러한 질환에 대한 인식 제고를 위한 이니셔티브가 증가하면서 예측 기간 동안 시장을 견인할 것으로 예상됩니다. 또한, 특허 만료의 증가와 제네릭 의약품의 시장 진입은 저렴한 가격으로 인해 감염증 치료제에 대한 수요를 증가시킬 것으로 예상됩니다.

또한, 이러한 감염성 질환의 진단 및 치료에 대한 상환이 가능하며, 이러한 질환의 발병률이 높은 지역에서 제조업체가 의약품을 무료로 배포하고 있는 것도 시장 성장을 촉진하는 요인으로 작용할 것으로 예상됩니다. 그러나 낮은 항감염증 약물의 보급률과 위조 의약품의 증가는 예측 기간 동안 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.

북미 시장은 2016년에 가장 큰 점유율을 차지했습니다. 많은 제조업체의 존재, 유리한 상환 시나리오, 의료비 증가가 이 지역이 가장 큰 점유율을 차지하는 주요 요인으로 작용하고 있습니다. 그러나 아시아태평양은 2017년부터 2025년까지 가장 높은 성장률을 보일 가능성이 높습니다. 높은 전염병 유병률, 아시아 국가들의 경제 상황 개선, 전염병 치료 보급을 위한 정부 이니셔티브 증가, 자금 조달 활동 증가 등이 예측 기간 동안 이 지역에서 가장 높은 성장률을 보일 것으로 예상됩니다.

감염증 치료제 시장 보고서 하이라이트

• 2024년 바이러스 감염증이 42.58%의 점유율로 시장을 장악했습니다. 기생충 감염 분야는 유병률 증가, 약제 내성 증가, 말라리아, 리슈만증, 주혈흡충증을 대상으로 한 세계 보건 이니셔티브에 힘입어 가장 빠르게 성장하는 시장입니다.
• 백신은 2024년 32.75%의 점유율을 차지하며 항감염증 치료제 시장을 장악했습니다. 이는 질병 유병률 증가, 인식 개선, 정부의 강력한 예방접종 프로그램에 힘입은 것입니다. 항기생충제 분야는 말라리아, 리슈만병, 기타 기생충 감염증의 유병률 증가로 인해 크게 성장하고 있습니다.
• 병원 약국은 전 세계 입원 건수 증가에 힘입어 2024년 52.19%의 매출 점유율로 시장을 주도했습니다. 기타 약국 분야는 감염증 치료제에 대한 접근성과 편의성을 높여주는 온라인 약국 도입 증가로 인해 빠르게 성장하고 있습니다.
• 2024년 감염증 치료제 시장에서 북미는 세계 점유율 38.09%를 차지하며 선두를 차지했습니다. 아시아태평양의 감염증 치료제 시장은 세균 및 바이러스 감염증의 유행 증가와 의료 인프라 개선으로 인해 확대되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 감염증 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 감염증 치료제에 대한 내성의 출현과 그에 따른 부작용
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 감염증 치료제 시장 : 감염증별 비즈니스 분석

• 감염증 시장 점유율, 2024년 및 2030년
• 감염증 부문 대시보드
• 시장 규모, 예측, 동향 분석(감염증별, 2018-2030년)
• 세균 감염증
• 바이러스 감염
• 진균 감염증
• 기생충 감염증

제5장 감염증 치료제 시장 : 약물 종류별 비즈니스 분석

• 약물 종류 시장 점유율, 2024년 및 2030년
• 약물 종류 부문 대시보드
• 시장 규모와 예측 및 동향 분석(약물 종류별, 2018-2030년)
• 항균제
• 항바이러스제
• 항진균제
• 항기생충제
• 백신
• 기타

제6장 감염증 치료제 시장 : 유통 채널별 비즈니스 분석

• 유통 채널 시장 점유율, 2024년 및 2030년
• 유통 채널 부문 대시보드
• 시장 규모, 예측, 동향 분석(유통 채널별, 2018-2030년)
• 병원 약국
• 소매 약국
• 기타

제7장 감염증 치료제 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018년부터 2030년까지 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 진출 기업 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Pfizer Inc.
  • AbbVie.
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Sandoz International GmbH
  • B. Braun SE
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • Bayer AG
  • AstraZeneca
  • Boehringer Ingelheim International GmbH.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd

ksm

영문 목차

영문목차

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 283.91 billion by 2030, registering a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

• Viral infections dominated the market with a 42.58% share in 2024. The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis.
• Vaccines dominated the anti-infective agents market with a 32.75% share in 2024, driven by rising disease prevalence, growing awareness, and strong government immunization programs. The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections.
• Hospital pharmacies dominated the market with a revenue share of 52.19% in 2024, driven by the rising number of hospitalizations globally.The other pharmacy segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics.
• North America holds a leading position in the 2024 infectious disease therapeutics market, accounting for 38.09% of the global share. The infectious disease therapeutics market in Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Infection
  • 1.2.2. Drug Class
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of infectious diseases
    • 3.2.1.2. Increasing incidence of infectious diseases
    • 3.2.1.3. Rising initiatives for the awareness of infectious diseases
  • 3.2.2. Market Restraint Analysis
• 3.3. 3.3.1 Emergence of resistance to infectious disease therapeutic drugs and adverse effects associated with them
• 3.4. Business Environment Analysis
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.4.1.1. Supplier Power
    • 3.4.1.2. Buyer Power
    • 3.4.1.3. Substitution Threat
    • 3.4.1.4. Threat of New Entrants
    • 3.4.1.5. Competitive Rivalry
  • 3.4.2. PESTLE Analysis
  • 3.4.3. Pipeline Analysis

Chapter 4. Infectious Disease Therapeutics Market: Infections Business Analysis

• 4.1. Infections Market Share, 2024 & 2030
• 4.2. Infections Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Infections, 2018 to 2030 (USD Million)
• 4.4. Bacterial Infections
  • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Viral Infections
  • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Human Immunodeficiency Virus (HIV/AIDS)
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Hepatitis (Hepatitis B, Hepatitis C)
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Influenza
    • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Fungal Infections
  • 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Parasitic Infections
  • 4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Antibacterials
  • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Antivirals
  • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Antifungals
  • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Antiparasitic Drugs
  • 5.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. Vaccines
  • 5.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospitals Pharmacies
  • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Infectious Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Pfizer Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Infection Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. AbbVie.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Infection Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Gilead Sciences, Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Infection Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol-Myers Squibb
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Infection Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck & Co., Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Infection Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Sandoz International GmbH
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Infection Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. B. Braun SE
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Infection Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Xellia Pharmaceuticals
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Infection Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Mankind Pharma
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Infection Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bayer AG
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Infection Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. AstraZeneca
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Infection Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Boehringer Ingelheim International GmbH.
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Infection Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Novartis AG
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Infection Benchmarking
    • 8.5.13.4. Strategic Initiatives
  • 8.5.14. F. Hoffmann-La Roche Ltd
    • 8.5.14.1. Overview
    • 8.5.14.2. Financial Performance
    • 8.5.14.3. Infection Benchmarking
    • 8.5.14.4. Strategic Initiatives

관련자료